FDA takes important step to increase the development of, and access to, abuse-deterrent opioids

The U.S. Food and Drug Administration today issued a draft guidance intended to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF) while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.
Source: FDA Press Releases